Synthesis of Tricyclic Condensed Rings Incorporating the Pyrazole or Isoxazole Moieties Bonded to a 4-Piperidinyl Substituent

Giansalvo Pinna 1,*, Giovanni Loriga 2, Gérard A. Pinna 1 and Giorgio Chelucci 3

1 Dipartimento di Chimica e Farmacia, Università di Sassari, Via F. Muroni 23/A, 07100 Sassari, Italy; E-Mail: pinger@uniss.it

2 C.N.R. Istituto di Farmacologia Traslazionale, UOS Cagliari, Edificio 5, Loc Piscinamanna, 09010 Pula (CA), Italy; E-Mail: giovanni.loriga@ift.cnr.it

3 Dipartimento di Agraria, Università di Sassari, Viale Italia 39, 07100 Sassari, Italy; E-Mail: chelucci@uniss.it

* Author to whom correspondence should be addressed; E-Mail: pinlab@uniss.it; Tel.: +39-079-228721; Fax: +39-079-22872.

Received: 3 June 2013; in revised form: 1 July 2013 / Accepted: 2 July 2013 / Published: 10 July 2013

Abstract: In this paper we report the synthesis of new compounds based on the pyrazole and isoxazole framework fused to a cycloalkene unit, and bearing as a substituent the 1-piperidinyl group as new examples of potential antipsychotic molecules. The general synthesis involves the acylation of a chloro-substituted cyclic ketone with a 1-substituted piperidine-4-carboxylate derivative, followed by heterocyclization of the formed 1,3-dioxo compound with a hydrazine or hydroxylamine.

Keywords: heterocyclization; hydrazine; hydroxylamine; tricyclic isoxazoles; tricyclic pyrazoles

1. Introduction

Among the compounds with antipsychotic properties [1] there are the heteropentalenes A–C [2], characterized by a pyrazole and isoxazole framework bonded to p-chlorophenyl and 4-piperidinyl substituents (Figure 1). In continuation of our interest in the field of the synthesis of biologically active
compounds [3], we have now devoted our attention to obtain tricyclic compounds E related to the heteropentalenes A–C as new potential antipsychotic compounds.

A well known strategy to affect the biological activity of organic compounds is to decrease their conformational flexibility. In fact, it has been proposed that appropriate structural constraints could restrict a pharmacophoric structural element to a sufficiently small region of conformational space thereby permitting the ligand to bind to its designated receptor with high affinity and selectivity [4,5]. A way to achieve this goal with heteropentalenes A–C could be to connect the unsubstituted central carbon of the heteropentalene and the α-carbon of the phenyl group with an alkylidene bridge (formula D, Figure 1).

In this line, we have developed a practical and extensible method to build compounds with a tricyclic framework incorporating the pyrazole and isoxazole framework and with the central ring that can be modulated in size, namely compounds with the general formula E shown in Figure 1. These new compounds share with A–C the chlorine on the aryl ring and the 4-(1-benzyl)- or 4-(1-phenylethyl)-piperidinyl substituents on the isoxazole and pyrazole moieties (Figure 1).

**Figure 1.** Leads and target molecules.

![Figure 1](https://example.com/figure1.png)

The planned retrosynthesis of the derivatives E is shown in Scheme 1. In this approach, the final heterocyclization of the 1,3-dioxo compounds F with hydrazine or hydroxylamine is preceded by acylation of the chloro-substituted cyclic ketones G with the 1-substituted piperidine-4-carboxylate derivatives H.

**Scheme 1.** Retrosynthesis approach.

![Scheme 1](https://example.com/scheme1.png)
2. Results and Discussion

To begin the synthesis of the target derivatives E (Scheme 1), the known cyclic ketones 1a–c [6,7] were acylated by reaction of the corresponding sodium enolate, obtained by reaction with sodium hydride, with the reagent formed by reaction of the N-Boc protected isonipecotic acid 9 with 1,1′-carbonyldiimidazole [8] (Scheme 2). In this way, 1,3-dicarbonyl derivatives 2a–c were obtained in 62–63% yields. Next, these compounds were submitted to N-deprotection by treatment with trifluoroacetic acid in CH2Cl2. However, while 2b and 2c were easily deprotected giving compounds 3b and 3c in high yields (92–95%), the removal of the N-Boc group from 2a failed. Further attempts to deprotect 2a with HCOOH, 3N HCl in AcOEt, CF3COOH and Et3SiH, and SnCl4 in AcOEt all failed unexpectedly, therefore, alternative approaches to the target compounds 6a, 7a and 8a were investigated next (see below).

Compounds 3b,c were converted in 59–72% yields into the related N-benzyl and N-phenylethyl derivatives 4b,c and 5b,c by reaction with benzyl chloride and 2-phenyl-1-iodoethane, respectively. With the key 1,3-dicarbonyl derivatives 4b,c and 5b,c in hand, their conversion into the desired derivatives E was pursued according to the planned retrosynthetic scheme. Compounds 4b,c and hydrazine in methanol were stirred at room temperature to afford the pyrazole derivatives 6b and 6c in good yields (78% and 50%, respectively). Treatment of 5b,c with hydroxylamine hydrochloride in EtOH/AcOH at 80 °C gave isoxazoles 7b,c and 8b,c as mixtures of regioisomers in moderate to good yields. With 5b isoxazoles 7b and 8b were obtained in a 4/1 ratio, while 5c gave isoxazoles 7c and 8c in a 3.2/1 ratio [9].

Reagents and conditions: (a) (i) NaH, DMF, rt; (ii) 9, 1,1′-carbonyldiimidazole, DMF, rt, 45 min; (iii) 120 °C, 6 h; (b) CF3COOH, CH2Cl2, rt, 2 h; (c) BnCl or BnCH2I. DMF, t-Pr2NEt, 25–60 °C, 12h; (d) H3N-NH2, MeOH, rt, 12 h; (e) NH2OH, EtOH, AcOH, 80 °C, 12 h.
To obtain compound 6a the synthetic routes outlined in Scheme 3 were followed. Firstly, the sodium enolate of the ketone 1a was reacted with phenyl 1-benzylpiperidine-4-carboxylate 12, but the 1,3-dicarbonyl intermediate 4a failed to give the expected pyrazole 6a by treatment with hydrazine in AcOH/MeOH at 80 °C. However, when the same enolate was treated with phenyl 1-(phenylcarbonyl)piperidine-4-carboxylate 13 [10], obtained by esterification with phenol of the parent acid (Scheme 5), the formed 1,3-dicarbonyl 10b afforded by treatment with hydrazine in AcOH/MeOH at 80 °C the substituted pyrazole 11 in 82% yield. Finally, LiAlH4 reduction of the carbonyl group to the methylene unit afforded the target pyrazole 6a in 80% yield (66% overall yield from 1a).

This satisfactory result appeared to open a way to isoxazoles 7a and 8a by simple replacing of the piperidine derivative 13 with the analogue 16 (Scheme 4). However, the treatment of the 1,3-dicarbonyl intermediate 14, obtained in turn by reaction of 1a with 16, with hydroxylamine hydrochloride in EtOH/AcOH at 80 °C failed to afford the expected isoxazoles 15. This unexpected result prompted us to verify another route based on the use of the N-benzylpiperidine 17 that was obtained by esterification with phenol of the parent acid (Scheme 5). We were pleased to find that the 1,3-dicarbonyl intermediate 5a, formed by reaction of the enolate of the ketone 1a with 17, could be directly converted in the usual way into a mixture of isoxazoles 7a and 8a in 41% and 12% yield, respectively (Scheme 4).

Scheme 3. Synthesis of compound 6a.

Reagents and conditions: (a) (i) NaH, benzene, rt, (b) 12, reflux, 3.5 h; (c) 13, reflux, 3.5 h; (d) H2N-NH2, AcOH, EtOH, 80 °C, 4 h; (e) LiAlH4, THF, rt, 12 h.
Scheme 4. Synthesis of compounds 7a and 8a.

Reagents and conditions: (a) (i) NaH, benzene, rt, (ii) 16, reflux; (b) NH₂OH, AcOH, EtOH, 80 °C; (c) (i) NaH, benzene, rt, (ii) 17, reflux, 4 h; (b) NH₂OH, AcOH, EtOH, 80 °C, 7 h.

Scheme 5. Synthesis of compounds 13 and 17.

Reagents and conditions: (a) PhOH, EDC, DMAP, CH₂Cl₂, 40 °C, 14 h.

3. Experimental

3.1. General

All reagents and solvents were purchased from commercial suppliers and used as received. Low boiling petroleum ether corresponds to the fraction collected between 40 and 60 °C. THF was distilled from sodium-benzophenone ketyl and degassed thoroughly with dry nitrogen directly before use. Melting points were determined on a Büchi 510 capillary apparatus and are uncorrected. IR spectra were recorded on a J ASCO FT/IR-460 plus equipment. The NMR spectra were obtained with a Varian VXR-300 spectrometer at 200 MHz for ¹H and 50 MHz for ¹³C. Chemical shifts are reported in ppm downfield from internal Me₄Si in CDCl₃. The following abbreviations were used to describe peak patterns where appropriate: singlet (s), doublet (d), triplet (t), multiplet (m) and broad resonances (br). Elemental analyses were performed on a Perkin-Elmer 240 B analyser. TLC was performed on Merck silica gel 60 TLC plates F254 and visualized using UV or phosphomolibdic acid. Flash chromatography was carried out on silica gel (40–60 mesh). The chloroketone 1a was a commercial compound. 6-Chloro-3,4-dihydronaphthalen-1-one (1b) [6], 7-chloro-2,3,4,5-tetrahydrobenzocyclo-
heptan-1-one (1c) [7], N-Boc-nipecotic acid [8] and the piperidines 18 [10] and 19 [11] were obtained following the corresponding literature procedures.

3.2. General Procedure for the Synthesis of the Compounds 2a–2c

A solution of 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (9, 2.85 g, 12.45 mmol) and 1,1′-carbonyldiimidazole (2.29 g, 14.11 mmol) in DMF (3 mL) was stirred at room temperature for 45 min. This solution was added dropwise to a solution prepared by stirring for 20 min the suitable ketone 1a, 1b or 1c (7.64 mmol) with NaH (60% in oil, 0.93 g, 23.20 mmol) in DMF (20 mL). The resulting mixture was heated for the appropriate time. After cooling, H2O was added and the mixture was extracted with Et2O (3 × 30 mL). The organic phase was dried over Na2SO4, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography.

tert-Butyl 4-(5-chloro-1-oxo-2,3-dihydro-1H-indene-2-carbonyl)piperidine-1-carboxylate (2a). According to the general procedure, the reaction between 1a and 9 was carried out at 30 °C for 7 h. The residue was purified by flash chromatography (petroleum ether/EtOAc = 9:1) affording 2a: yield 66%; red solid; Mp 102–103 °C. Rf = 0.10 (petroleum ether/AcOEt = 9:1). 1H-NMR: δ 1.48 (s, 9H), 1.60–1.95 (m, 4H), 2.40–2.64 (m, 1H), 2.64–2.98 (m, 2H), 3.62 (s, 2H), 4.13–4.33 (m, 2H), 7.40 (d, 1H, J = 8.0 Hz), 7.48 (s, 1H), 7.74 (d, 1H, J = 8.0 Hz), 13.80 (brs, 1H). 13C-NMR: δ 27.9 (CH2), 28.4 (3 × CH3), 29.8 (2 × CH2), 41.8 (CH), 43.4 (2 × CH2), 79.7 (C), 108.8 (C), 124.2 (CH), 126.0 (CH), 128.1 (CH), 136.7 (C), 139.1 (C), 148.6 (C), 154.7(CO), 182.7 (CO), 191.3 (COH). IR: (nujol) ν 1703 (CO), 1655 (CO), 1605 (CO) cm⁻¹. Anal. Calcd for C20H24ClNO4: C, 63.57; H, 6.40; N, 3.71. Found: C, 63.65; H, 6.49; N, 3.81.

tert-Butyl 4-(6-chloro-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carbonyl)piperidine-1-carboxylate (2b). According to the general procedure, the reaction between 1b and 9 was carried out at 110 °C for 7 h. The residue was purified by flash chromatography (petroleum ether/EtOAc = 8:2) affording 2b: yield 63%; red solid; Mp 120–121 °C. Rf = 0.43 (petroleum ether/AcOEt = 8:2). 1H-NMR: δ 1.47 (s, 9H), 1.59–1.87 (m, 5H), 2,67 (d, 2H, J = 7.4 Hz), 2.80–2.88 (m, 4H), 4.18 (d, 2H, J = 7.4 Hz), 7.24 (d, 1H, J = 10.2 Hz), 7.31 (s, 1H), 7.87 (d, 1H, J = 8.2 Hz), 16.65 (s, 1H). 13C-NMR: δ 21.9 (CH2), 27.8 (CH2), 28.4 (3 × CH3), 29.3 (2 × CH2), 41.4 (CH), 43.3 (2 × CH2), 79.6 (C), 104.6 (C), 126.2 (CH), 127.2 (CH), 127.3 (CH), 127.5 (C), 136.7 (C), 142.2 (C), 157.3 (CO), 179.0 (CO), 197.8 (COH). IR: (nujol) ν 1703 (CO), 1650 (CO), 1605 (CO) cm⁻¹. Anal. Calcd for C21H26ClNO4: C, 63.57; H, 6.40; N, 3.71. Found: C, 63.65; H, 6.49; N, 3.81.

tert-Butyl 4-(2-chloro-5-oxo-6,7,8,9-tetrahydro-5H-annulene-6-carbonyl)piperidine-1-carboxylate (2c). According to the general procedure the reaction between 1c and 9 was carried out at 70 °C for 7 h. The residue was purified by flash chromatography (petroleum ether/EtOAc = 8:2) affording 2c: yield 63%; yellow solid; Mp 134–136 °C. Rf = 0.31 (petroleum ether/AcOEt = 9:1). 1H-NMR: δ 1.48 (s, 9H), 1.53–1.92 (m, 7H), 1.92–2.13 (m, 1H), 2.18 (t, 2H, J = 6.8 Hz), 2.55–2.90 (m, 3H), 4.10–4.31 (m, 2H), 7.21 (s, 1H), 7.27–7.42 (m, 1H), 7.57 (d, 1H, J = 8.2 Hz), 16.78 (s, 1H). 13C-NMR: δ 22.7 (CH2), 28.3 (3 × CH2), 28.5 (CH3), 31.1 (CH2), 31.3 (2 × CH2), 40.9 (CH), 43.2 (2 × CH2), 79.5 (C), 108.2 (C), 126.8 (CH), 128.7 (CH), 129.0 (CH), 131.0 (C), 136.4 (C), 141.4 (C),
Molecules 2013, 18 8153

154.5 (CO), 186.2 (CO), 194.4 (COH). IR: (nujol) ν 1706 (CO), 1652 (CO), 1613 (CO) cm⁻¹. Anal. Calcd for C₂₂H₂₈ClNO₄: C, 65.10; H, 6.95; N, 3.45. Found: C, 66.08; H, 6.98; N, 3.42.

3.3. General Procedure for the Synthesis of Compounds 3b, 3c

A solution of CF₃COOH (1.46 g, 12.8 mmol) in CH₂Cl₂ (4.6 mL) was added dropwise to a solution of the 1,3-dicarbonyl compound 2b or 2c (1.28 mmol) in CH₂Cl₂ (9.2 mL). After stirring 2 h at room temperature, CH₂Cl₂ was added. The resulting mixture was washed two times with a 10% solution of K₂CO₃ and then with H₂O. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography.

6-Chloro-2-(piperidine-4-carbonyl)-3,4-dihydronaphthalen-1(2H)-one (3b). Compound 2b was converted into the title product 3b according to the general procedure. The residue was purified by flash chromatography (CHCl₃/MeOH = 8:2) affording 3b: yield 63%; yellow solid; Mp 150–154 °C. Rf = 0.10 (CHCl₃/MeOH 8:2); ¹H-NMR: δ 2.62–2.85 (m, 4H), 2.58–2.77 (m, 4H), 2.80–2.95 (m, 4H), 3.10-3.34 (m, 2H), 7.21 (s, 1H), 7.32 (d, 1H, J = 8.2 Hz), 7.86 (d, 1H, J = 8.2 Hz), 8.52–9.20 (brs, 1H). ¹³C-NMR: δ 21.9 (CH₂), 27.5 (CH₂), 31.3 (2 × CH₂), 42.0 (CH), 45.1 (2 × CH₂), 109.2 (C), 126.3 (CH), 127.4 (CH), 129.1 (CH), 137.0 (C), 137.2 (C), 144.5(C), 189.0 (CO), 192.4 (COH). IR: (nujol) ν 3453 (NH), 1701 (CO), 1680 (CO) cm⁻¹. Anal. Calcd for C₁₆H₁₈ClNO₂: C, 65.86; H, 6.22; N, 4.80. Found: C, 65.56; H, 6.26; N, 4.83.

2-Chloro-6-(piperidine-4-carbonyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (3c). Compound 2c was converted into the title product 3c according to the general procedure. The residue was purified by flash chromatography (CHCl₃/MeOH = 8:2) affording 3c: yield 63%; white solid; Mp 138–142 °C. Rf = 0.11 (CHCl₃/MeOH = 8:2); ¹H-NMR: δ 1.60–1.92 (m, 4H), 1.92–2.10 (m, 2H), 2.18 (t, 2H, J = 6.2 Hz), 2.58–2.85 (m, 5H), 2.90–2.98 (m, 1H), 3.12–3.28 (m, 2H), 7.21 (s, 1H), 7.33 (d, 1H, J = 8.0 Hz), 7.56 (d, 1H, J = 8.0 Hz), 8.00–9.00 (brs, 1H). ¹³C-NMR: δ 22.8 (CH₂), 28.7 (CH₂), 31.1 (2 × CH₂), 31.5 (CH), 40.6 (CH₂), 45.1 (2 × CH₂), 108.2 (C), 126.8 (CH), 128.7 (CH), 129.0 (CH), 136.0 (C), 136.8 (C), 141.5 (C), 188.0 (CO), 194.4 (COH). IR: (nujol) ν 3,430 (NH), 1,701 (CO), 1,680 (CO) cm⁻¹. Anal. Calcd for C₁₇H₁₈ClNO₂: C, 66.77; H, 6.59; N, 4.58. Found: C, 67.37; H, 6.64; N, 4.53.

3.4. General Procedure for the Synthesis of the Compounds 4b, 4c and 5b, 5c

To a solution of the 1,3-dicarbonyl compound 3b or 3c (3.27 mmol) in DMF (18.25 mL) was added i-Pr₂NEt (0.59 g, 4.58 mmol) and then the appropriate halide (1.1 eq). The mixture was then stirred at room temperature or heated under reflux for the necessary time. Water was added and the mixture was extracted with AcOEt. The organic phase was washed with brine, dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography.

2-(1-Benzylpiperidine-4-carbonyl)-6-chloro-3,4-dihydronaphthalen-1(2H)-one (4b). A solution of the ketone 3b and benzyl chloride in DMF was stirred at room temperature for 12 h. After workup the residue was purified by flash chromatography (petroleum ether/EtOAc = 1:1) affording 4b: yield 59%; brown oil; Rf = 0.46 (petroleum ether/EtOAc = 1:1); ¹H-NMR: δ 1.51–1.80 (m, 4H), 1.90 (d, 2H,
J = 11 Hz), 2.03 (d, 2H, J = 13.2 Hz), 2.58–2.76 (m, 1H), 2.84 (t, 2H, J = 7.4 Hz), 3.00 (d, 2H, J = 9.6 Hz), 3.55 (s, 2H), 7.20 (s, 1H), 7.29–7.40 (m, 6H), 7.86 (d, 1H, J = 8.6 Hz), 16.68 (s, 1H). 13C-NMR: δ 22.8 (CH2), 28.6 (CH2), 32.1 (2 × CH2), 33.5 (CH), 45.1 (2 × CH2), 64.5 (CH2), 118.4 (C), 126.7 (CH), 126.9 (CH), 127.5 (CH), 128.3 (2 × CH2), 128.6 (CH), 128.9 (CH), 129.1 (C), 129.3 (CH), 131.2 (C), 139.6 (C), 142.3 (C), 184.9 (CO), 195.3 (COH) IR: (nujol) ν 1,710 (CO), 1,682 (CO) cm⁻¹. Anal. Calcd for C23H24ClNO2: C, 72.34; H, 6.33; N, 3.67. Found: C, 72.41; H, 6.38; N, 3.75.

6-(1-Benzylpiperidine-4-carbonyl)-2-chloro-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (4c). A solution of the ketone 3c and benzyl chloride in DMF was stirred at room temperature for 12 h. After workup, the residue was purified by flash chromatography (petroleum ether/EtOAc = 1:1) affording 4c: yield 72%; brown oil; Rf = 0.37 (petroleum ether/EtOAc = 1:1); 1H-NMR: δ 1.61–2.24 (m, 8H), 2.53–2.76 (m, 2H), 2.76–3.11 (m, 5H), 3.54 (s, 2H), 7.00–7.48 (m, 6H), 7.55 (d, 1H, J = 8.2 Hz), 8.00 (s, 1H), 16.8 (s, 1H). 13C-NMR: δ 22.9 (CH2), 28.5 (CH2), 31.0 (2 × CH2), 31.4 (CH2), 31,6 (CH), 52.8 (2 × CH2), 62.9 (CH2), 108.4 (C), 126.6 (CH), 126.8 (CH), 127.2 (CH), 127.5 (CH), 128.0 (CH), 128.3 (2 × CH), 128.7 (CH), 129.3 (C), 131.0 (C), 139.6 (C), 145.1 (C), 194.9 (CO), 195.3 (COH). Anal. IR: (nujol) ν 1,705 (CO), 1,682 (CO) cm⁻¹. Calcd for C24H26ClNO2: C, 72.81; H, 6.62; N, 3.54. Found: C, 72.21; H, 6.65; N, 3.57.

6-Chloro-2-(1-phenethylpiperidine-4-carbonyl)-3,4-dihydronaphthalen-1(2H)-one (5b). A solution of the ketone 3b and phenylethyl iodide in DMF was heated at 60 °C for 12 h. After workup, the residue was purified by flash chromatography (petroleum ether/EtOAc = 2:8) affording 5b: yield 70%; brown oil; Rf = 0.42 (petroleum ether/EtOAc = 1:1); 1H-NMR: δ 1.26–2.53 (m, 8H), 2.75–2.99 (m, 2H), 3.04–3.23 (m, 2H), 7.08–7.45 (m, 6H), 7.49 (m, 1H), 7.71 (d, 1H, J = 9.0 Hz), 14,27 (s, 1H). 13C-NMR: δ 22.8 (CH2), 28.7 (CH2), 32.1 (CH2), 32.6 (2 × CH2), 33.5 (CH), 45.3 (2 × CH2), 64.5 (CH2), 117.9 (C), 126.6 (CH), 128.3 (CH), 128.8 (CH), 128.9 (2 × CH), 129.1 (2 × CH), 129.2 (CH), 131.2 (C), 139.6 (C), 141.5 (C), 142.3 (C), 194.9 (CO), 195.3 (COH) Anal. IR: (nujol) ν 1,700 (CO), 1,681 (CO) cm⁻¹. Calcd for C24H26ClNO2: C, 72.81; H, 6.62; N, 3.54. Found: C, 72.11; H, 6.66; N, 3.58.

2-Chloro-6-(1-phenethylpiperidine-4-carbonyl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one (5c). A solution of the ketone 3c and phenylethyl iodide in DMF was heated at 60 °C for 12 h. After workup, the residue was purified by flash chromatography (CHCl3/acetone = 9:1) affording 5c: yield 62%; brown oil; Rf = 0.33 (CHCl3/acetone = 9:1); 1H-NMR: δ 1.72–1.89 (m, 3H), 1.95–2.28 (m, 7H), 2.53–2.92 (m, 7H), 3.12 (d, 2H, J = 9.6), 7.20 (s, 1H), 7.23–7.25 (m, 6H), 7.56 (d, 1H, J = 8.4 Hz), 16.7 (s, 1H). 13C-NMR: δ 22.8 (CH2), 28.8 (CH2), 31.2 (CH2), 31.7 (2 × CH2), 33.5 (CH2), 41.0 (CH), 53.2 (2 × CH2), 60.7 (CH2), 108.3 (CH), 126.0 (CH), 126.6 (CH), 126.8 (CH), 127.5 (2 × CH), 128.3 (CH), 128.6 (2 × CH), 128.7 (C), 129.1 (C), 131.0 (C), 141.5 (C), 187.9 (CO), 195.3 (COH). IR: (nujol) ν 1,699 (CO), 1,676 (CO) cm⁻¹. Anal. Calcd for C25H28ClNO2: C, 73.25; H, 6.88; N, 3.42. Found: C, 73.76; H, 6.84; N, 3.46.
3.5. General Procedure for the Synthesis of Compounds 6b, 6c

A solution of the 1,3-dicarbonyl compound 4b or 4c (0.68 mmol) and hydrazine hydrate (0.32 g, 6.39 mmol) in MeOH (9 mL) was stirred overnight at room temperature. Water was added and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography.

3-(1-Benzylpiperidin-4-yl)-7-chloro-4,5-dihydro-1H-benzo[g]indazole (6b). Compound 4b was converted into the title product 6b according to the general procedure. After workup, the residue was purified by flash chromatography (CHCl₃/acetone = 9:1) affording 6b: yield 78%; yellow solid; Mp 173–174 °C; Rf = 0.51 (CH₂Cl₂/MeOH = 95:5); ¹H-NMR: δ 1.80–2.27 (m, 6H), 2.71–2.82 (m, 3H), 2.91 (t, 2H, J = 7.2 Hz), 3.01 (t, 2H, J = 7.2 Hz), 3.56 (s, 2H), 7.20–7.40 (m, 7H), 7.64–7.71 (m, 1H). ¹³C-NMR: δ 18.9 (CH₂), 29.6 (CH₂), 31.3 (2×CH₂), 33.7 (CH), 53.6 (2×CH₂), 63.3 (CH₂), 111.2 (C) 123.2 (CH), 126.9 (CH), 127.1 (CH), 127.4 (CH), 127.5 (C), 128.2 (2×CH), 129.2 (2×CH), 132.7 (C), 137.8 (C), 138.3 (C). 142.3 (CN), 142.8 (CN). Anal. Calcd for C₂₃H₂₄ClN₃: C, 73.10; H, 6.40; N, 11.12. Found: C, 73.91; H, 6.43; N, 11.07.

3-(1-Benzylpiperidin-4-yl)-8-chloro-1,4,5,6-tetrahydrobenzo[3,4]cycloepta[2,1-c]pyrazole (6c). Compound 4c was converted into the title product 6c according to the general procedure. After elaboration, the residue was purified by flash chromatography (CHCl₃/acetone = 9:1) affording 6c: yield 50%; yellow solid; Mp 165–166 °C; Rf = 0.51 (CH₂Cl₂/MeOH = 95:5); ¹H-NMR: δ 1.68–2.32 (m, 8H), 2.51–2.90 (m, 5H), 3.04 (d, 2H, J = 9.8 Hz), 3.59 (s, 2H), 7.10–7.42 (m, 7H), 7.60–7.72 (m, 1H), 9.10–10.01 (brs, 1H). ¹³C-NMR: δ 24.1 (CH₂), 26.9 (CH₂), 29.7 (CH₂), 31.0 (2×CH₂), 34.8 (CH), 53.8 (2×CH₂), 63.2 (CH₂), 112.5 (C), 125.7 (CH), 126.4 (CH), 127.1 (CH), 127.4 (CH), 127.5 (2×CH), 128.2 (2×CH), 129.3 (2×C), 129.6 (C), 134.5 (C) 141.3 (CN), 142.8 (CN). Anal. Calcd for C₂₄H₂₆ClN₃: C, 73.55; H, 6.69; N, 10.72 Found: C, 73.25; H, 6.88; N, 10.42.

3.6. 1H-1-Oxa-2-aza-7-chloro-3-(1-phenethylpiperidin-4-yl)-4,5-dihydronaphto[2,1-d]isoxazole (7b) and 1H-1-oxa-2-aza-8-chloro-3-(1-phenethylpiperidin-4-yl)-5,6-dihydro-4H-benzo[3,4]cycloepta[1,2-d]isoxazole (7c)

A solution of the 1,3-dicarbonyl compound 5b or 5c (2.44 mmol) and hydroxylamine hydrochloride (1.02 g, 14.64 mmol) in EtOH (12.2 mL) containing 4 drops of AcOH was heated under reflux for 24 h. Water was added and the mixture was extracted with CHCl₃. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (CHCl₃/MeOH = 97:3) to give 7b or 7c.

Compound 7b. Yield 20%; brown solid; Mp 170–172 °C; Rf = 0.11 (CHCl₃/MeOH = 97:3); ¹H-NMR (DMSO-d₆): δ 1.50–1.80 (m, 9H), 1.42–2.10 (m, 4H), 2.48 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H, J = 7.0 Hz), 7.12–7.42 (m, 8H). ¹³C-NMR: δ 28.4 (CH₂), 29.5 (CH₂), 32.7 (CH₂), 38.2 (2×CH₂), 40.7 (CH), 52.7 (2×CH₂), 59.7 (CH₂), 117.8 (C), 125.0 (CH), 125.4 (CH), 125.8 (CH), 126.5 (CH), 127.9 (2×CH), 128.2 (2×CH), 128.6 (C), 130.9 (C), 136.4 (C), 144.1 (C), 157.3 (CN), 166.1 (CO). Anal. Calcd for C₂₄H₂₅ClN₂O: C, 73.36; H, 6.41; N, 7.13. Found: C, 73.96; H, 6.44; N, 7.10.

Compound 7c. Yield 25%; brown solid; Mp 185–187 °C; Rf = 0.10 (CHCl₃/MeOH = 97:3); ¹H-NMR (DMSO-d₆): δ 1.55–1.80 (m, 9H), 1.42–2.10 (m, 4H), 2.48 (t, 2H, J = 7.0 Hz), 2.69 (t, 2H, J = 7.0 Hz), 7.12–7.42 (m, 8H). ¹³C-NMR: δ 28.4 (CH₂), 29.5 (CH₂), 32.7 (CH₂), 38.2 (2×CH₂), 40.7 (CH), 52.7 (2×CH₂), 59.7 (CH₂), 117.8 (C), 125.0 (CH), 125.4 (CH), 125.8 (CH), 126.5 (CH), 127.9 (2×CH), 128.2 (2×CH), 128.6 (C), 130.9 (C), 136.4 (C), 144.1 (C), 157.3 (CN), 166.1 (CO). Anal. Calcd for C₂₄H₂₅ClN₂O: C, 73.36; H, 6.41; N, 7.13. Found: C, 73.96; H, 6.44; N, 7.10.
Compound 7c. Yield 35%; brown solid; Mp 114–117 °C; \( R_f = 0.24 \) (CHCl₃/Methanol = 8:2); \(^{1}\)H-NMR (DMSO-d₆): \( \delta \) 1.82–2.10 (m, 4H), 2.11–2.33 (m, 4H), 2.60–2.76 (m, 5H), 2.70–2.98 (m, 4H), 3.10–3.21 (m, 2H), 7.12–7.20 (m, 7H), 7.88 (d, 1H, \( J = 8.2 \) Hz). \(^{13}\)C-NMR: \( \delta \) 23.9 (CH₂), 24.5 (CH₂), 29.8 (2 x CH₂), 33.6 (CH₂), 35.2 (CH), 53.5 (2 x CH₂), 60.7 (CH₂), 113.8 (C), 126.1 (CH), 126.7 (CH), 128.1 (CH), 128.2 (CH), 128.3 (2 x CH), 128.6 (2 x CH), 129.6 (C), 134.7 (C), 141.5 (C), 142.1 (C), 161.2 (CN), 166.6 (CO) Anal. Calcd for C₂₅H₂₇ClN₂O: C, 73.79; H, 6.69; N, 6.88. Found: C, 73.25; H, 6.71; N, 6.91.

3.7. 2H-1-Aza-2-oxa-7-chloro-3-(1-phenethylpiperidin-4-yl)-4,5-dihydronaphto[1,2-c]isoxazole (8b) and 2H-1-aza-2-oxa-8-chloro-3-(1-phenethylpiperidin-4-yl)-5,6-dihydro-4H-benzo[3,4]cycloepta[2,1-c]isoxazole (8c)

A solution of the 1,3-dicarbonyl compound 5b or 5c (2.44 mmol) and hydroxylamine hydrochloride (1.02 g, 14.64 mmol) in EtOH (12.2 mL) containing 15 drops of AcOH was heated under reflux for 24 h. After cooling, H₂O was added and the mixture was extracted with CHCl₃. The organic phase was dried over Na₂SO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (CHCl₃/acetone = 8:2) to give 8b or 8c.

Compound 8b. Yield 5%; brown solid; Mp 165–166 °C; \( R_f = 0.24 \) (CHCl₃/acetone = 97:3); \(^{1}\)H-NMR (CDCl₃/DMSO-d₆): \( \delta \) 1.43–1.70 (m, 4H), 1.71–1.93 (m, 4H), 1.95–2.10 (m, 1H), 2.42–2.65 (m, 4H), 2.52 (t, 2H, \( J = 7.2 \) Hz), 2.65 (t, 2H, \( J = 7.2 \) Hz), 7.05–7.38 (m, 5H), 7.42–7.84 (m, 2H), 8.32 (d, 1H, \( J = 9.2 \) Hz). \(^{13}\)C-NMR (CDCl₃/DMSO-d₆): \( \delta \) 28.3 (CH₂), 29.5 (CH₂), 32.6 (CH₂), 38.2 (2 x CH₂), 40.7 (CH), 53.1 (2 x CH₂), 59.8 (CH₂), 118.0 (C), 120.2 (CH), 124.1 (CH), 125.4 (CH), 125.0 (CH), 125.8 (2 x CH), 127.9 (2 x CH), 128.6 (C), 131.2 (C), 134.8 (C), 140.3 (C), 161.2 (CN), 167.9 (CO). Anal. Calcd for C₂₄H₂₅ClN₂O: C, 73.36; H, 6.41; N, 7.13. Found: C, 72.86; H, 6.44; N, 7.01.

Compound 8c. Yield 12%; light brown solid; Mp 125–126 °C; \( R_f = 0.47 \) (CHCl₃/acetone = 8:2); \(^{1}\)H-NMR: \( \delta \) 1.95–2.38 (m, 8H), 2.52–2.78 (m, 5H), 2.78–3.01 (m, 4H), 3.15 (d, 2H, \( J = 9.6 \) Hz), 7.08–7.40 (m, 7H), 7.89 (d, 1H, \( J = 8.4 \) Hz). \(^{13}\)C-NMR: \( \delta \) 20.7 (CH₂), 27.0 (CH₂), 29.2 (CH₂), 33.0 (2 x CH₂), 33.2 (CH₂), 39.3 (CH), 53.1 (2 x CH₂), 60.4 (CH₂), 111.2 (C), 126.3 (CH), 126.7 (CH), 126.8 (CH), 127.8 (CH), 128.5 (2 x CH), 128.7 (2 x CH₂), 129.2 (C), 129.7 (C), 135.2 (C), 142.7 (C), 161.8 (CN), 170.4 (CO). Anal. Calcd for C₂₅H₂₇ClN₂O: C, 73.79; H, 6.62; N, 6.83. Found: C, 73.19; H, 6.62; N, 6.83.

(4-(6-Chloro-1,4-dihydroinden[1,2-c]pyrazol-3-yl)piperidin-1-yl)(phenyl)metanone (11). 5-Chloro-2,3-dihydro-1H-inden-1-one 1a (0.2 g, 1.23 mmol) and NaH (60% in oil, 0.12 g, 3.08 mmol) were added in sequence to a solution of phenyl 1-(phenylcarbonyl)piperidine-4-carboxylate 13 (0.33 g, 1.23 mmol) and the resulting mixture was heated under reflux for 3.5 h. After cooling a 50% aqueous solution of acetic acid was added and the resulting mixture was concentrated under reduced pressure. The residue was taken up in EtOH (4 mL) and AcOH (0.21 mL, 3.69 mmol). Hydrazine hydrate (0.09 mL, 1.85 mmol) was added and the resulting mixture was heated under reflux for 4 h. After cooling, the solvent was evaporated under reduced pressure and the residue was taken up in CH₂Cl₂. The organic phase was dried over Na₂SO₄, filtered and the solvent removed under reduced pressure.
The residue was purified by flash chromatography (CHCl₃/acetone = 95:5) affording **11**: yield 82%; yellow solid; Mp 167–170 °C; \( R_f = 0.24 \) (CHCl₃/MeOH = 95:5); \(^1\)H-NMR: \( \delta \) 1.58–2.21 (m, 6H), 2.93–3.21 (m, 3H), 3.63 (s, 2H), 7.33 (d, 1H, \( J = 8.0 \) Hz), 7.37–7.50 (m, 6H), 7.6 (d, 1H, \( J = 8.0 \) Hz). \(^{13}\)C-NMR: \( \delta \) 27.3 (CH₂), 29.1 (2 × CH₂), 29.4 (CH), 34.2 (2 × CH₂), 120.7 (C), 126.2 (CH), 126.8 (CH), 127.3 (CH), 128.5 (2 × CH), 129.8 (2 × CH₂), 129.9 (CH), 132.1 (C), 132.7 (C), 133.8 (C), 141.6 (C), 150.1 (CN) 157.3 (CN), 170.5 (CO). Anal. Calcd for C\(_{22}\)H\(_{20}\)ClN\(_3\)O: C, 69.93; H, 5.33; N, 11.12. Found: C, 70.34; H, 5.31; N, 11.17.

3-(1-Benzylpiperidin-4-yl)-6-chloro-1,4-dihydroindeno[1,2-c]pyrazole (6a). A solution of the amide **11** (0.14 g, 0.37 mmol) in THF (2 mL) was added dropwise to a suspension of LiAlH₄ (56.0 mg, 1.48 mmol) in THF (2 mL) at 0 °C. After stirring at room temperature for 12 h the mixture was diluted with Et₂O (2,5 mL) and then NaOH (1 M, 0.1 mL) e H₂O (0.3 mL) were added. The formed solid was filtered and diluted with CH₂Cl₂. The organic phase was dried over anhydrous Na₂SO₄, filtered and the solvent was removed under reduced pressure. The residue was purified by flash chromatography (CHCl₃/acetone = 95:5) affording **6a**: yield 80%; yellow solid; Mp 146–148 °C; \( R_f = 0.25 \) (CHCl₃/MeOH 95:5); \(^1\)H-NMR: \( \delta \) 1.75–2.16 (m, 6H), 2.60–2.80 (m, 1H), 2.95 (m, 2H), 3.50 (m, 1H), 3.53 (s, 2H), 7.17–7.37 (m, 6H), 7.42 (s, 1H), 7.61 (d, 1H, \( J = 8.0 \) Hz), 9.25–10.35 (brs, 1H). \(^{13}\)C-NMR: \( \delta \) 28.7 (CH₂), 30.3 (2 × CH₂), 31.0 (CH), 52.5 (2 × CH₂), 62.3 (CH₂), 119.7 (C), 125.3 (CH), 126.2 (CH), 126.6 (CH), 127.6 (2 × CH), 128.8 (2 × CH), 130.8 (CH), 133.0 (C), 136.5 (C), 141.1 (C), 141.4 (C) 143.6 (CN) 149.7 (CN). Anal. Calcd for C\(_{22}\)H\(_{22}\)ClN\(_3\): C, 72.62; H, 6.09; N, 11.55. Found: C, 72.70; H, 6.15; N, 11.59.

3.8. \( 1H-1\)-Oxa-2-aza-6-chloro-3-(1-phenethylpiperidin-4-yl)-1,4dihydroindeno[2,1-d]isoxazole (7a) and 2H-1-aza-2-oxa-6-chloro-3-(1-phenethylpiperidin-4-yl)-1,4dihydroindeno[1,2-c]isoxazole (8a)

To a solution of phenyl 1-(phenylethyl)piperidine-4-carboxylate **17** (0.50 g, 1.23 mmol) were added in sequence 5-chloro-2,3-dihydro-1\(^\text{H}\)-inden-1-one **1a** (0.2 g, 1.23 mmol) and NaH (60% in oil, 0.12 g, 3.08 mmol). The resulting mixture was heated under reflux for 4 h. After cooling a 50% aqueous solution of acetic acid was added and the resulting mixture was concentrated under reduced pressure. To the residue was taken up in EtOH (5 mL), AcOH (0.21 mL, 3.69 mmol) and hydroxylamine hydrochloride (0.128 mg, 1.85 mmol) was added. The resulting mixture was heated under reflux for 8 h. The solvent was evaporated under reduced pressure and the residue was taken up in CH₂Cl₂. The organic phase was dried over Na₂SO₄, filtered and the solvent removed under reduced pressure. The residue was purified by flash chromatography (CHCl₃/acetone = 8:2) to give **7a** and **8a**.

**Compound 7a.** Yield 12%; brown solid; Mp 149–151 °C; \( R_f = 0.20 \) (CHCl₃/acetone = 8:2); \(^1\)H-NMR: \( \delta \) 1.60–2.04 (m, 9H), 2.49 (t, 2H, \( J = 7.2 \) Hz), 2.62 (t, 2H, \( J = 7.2 \) Hz), 3.55 (s, 2H) 7.23–7.42 (m, 8H). \(^{13}\)C-NMR: \( \delta \) 28.8 (CH₂), 30.6 (CH₂), 31.1 (2 × CH₂), 31.7 (CH), 52.5 (2 × CH₂), 62.4 (CH₂), 119.7 (C), 125.4 (CH), 126.2 (CH), 126.7 (CH), 127.8 (2 × CH), 128.8 (2 × CH), 130.9 (CH), 134.0 (C), 136.0 (C), 142.5 (C), 153.7 (C), 161.0 (CN), 166.4 (CO). Anal. Calcd for C\(_{23}\)H\(_{23}\)ClN\(_2\)O: C, 72.91; H, 6.12; N, 7.39. Found: C, 73.12; H, 6.10; N, 7.43.
**Compound 8a.** Yield 41%; brown solid; Mp 157–160 °C; \( R_f = 0.41 \) (CHCl₃/MeOH 8:2); \(^1\)H-NMR (DMSO-d₆): \( \delta \) 1.82–2.10 (m, 5H), 2.11–2.33 (m, 4H), 2.60–2.70 (m, 2H), 2.73–2.88 (m, 2H), 3.57 (s, 2H), 7.12–7.28 (m, 8H). \(^{13}\)C-NMR: \( \delta \) 28.8 (CH₂), 30.5 (CH₂), 31.2 (2 x CH₂), 31.4 (CH), 53.2 (2 x CH₂), 62.3 (CH₂), 119.6 (C), 125.3 (CH), 126.5 (CH), 126.6 (CH), 127.8 (2 x CH₂), 128.8 (2 x CH₂), 130.9 (CH) 134.1 (C), 136.5 (C), 142.4 (C), 151.9 (C), 162.3 (CN) 169.2 (CO). Anal. Calcd for C₂₃H₂₃ClN₂O: C, 72.91; H, 6.12; N, 7.39. Found: C, 73.10; H, 6.14; N, 7.46.

**3.9. Phenyl 1-benzoylpiperidine-4-carboxylate (13) and phenyl 1-phenethylpiperidine-4-carboxylate (17)**

A mixture of the acid \( 18 \) or \( 19 \) (2.19 mmol) in CH₂Cl₂ (40 ml), 1-3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.84 g, 4.38 mmol), dimethylaminopiridine (0.54 g, 4.38 mmol) and phenol (0.62 g, 6.57 mmol) was heated under reflux for 14 h. After cooling, the reaction mixture was diluted with CH₂Cl₂ and washed with a saturated NH₄Cl solution (3 x 20 mL). The separated organic phase was dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by flash chromatography affording the product \( 13 \) or \( 17 \).

**Compound 13.** purified by flash chromatography by using as the eluent petroleum ether/EtOAc = 1:1; yield 62%; yellow oil; \( R_f = 0.46 \) (petroleum ether/EtOAc = 1:1); \(^1\)H-NMR: \( \delta \) 1.65–2.10 (m, 6H), 2.70–2.90 (m, 1H), 3.10–3.25 (m, 2H), 7.00–7.45 (m, 10H). \(^{13}\)C-NMR: \( \delta \) 28.2 (2 x CH₂), 41.1 (CH), 46.8 (2 x CH₂), 121.3 (2 x CH), 125.9 (CH), 126.8 (2 x CH), 128.4 (2 x CH), 129.4 (2 x CH), 129.6 (CH), 135.8 (C), 150.4 (C), 170.4 (CO), 172.6 (CO). IR: (nujol) \( \nu \) 1,752 (CO), 1,628 (CO) cm⁻¹. Anal. Calcd for C₁₉H₁₉NO₃: C, 73.77; H, 6.19; N, 4.53. Found: C, 73.85; H, 6.25; N, 4.46.

**Compound 17.** purified by flash chromatography by using as the eluent CHCl₃/MeOH = 9:1; yield 64%; yellow oil; \( R_f = 0.27 \) (CHCl₃/MeOH = 9:1); \(^1\)H-NMR: \( \delta \) 1.80–2.20 (m, 4H), 2.56–2.65 (m, 2H), 2.80–2.90 (m, 3H), 3.00–3.15 (m, 2H), 3.43 (t, 2H, \( J = 5.4 \) Hz), 7.06 (d, 2H, \( J = 8.4 \) Hz), 7.20-7.42 (m, 8H). \(^{13}\)C-NMR: \( \delta \) 28.2, (2 x CH₂) 33.8 (CH₂), 41.1 (CH), 46.8 (2 x CH₂), 57.4 (CH₂), 122.5 (2 x CH), 126.9 (2 x CH), 127.3 (CH), 128.4 (2 x CH), 129.0 (2 x CH), 129.5 (CH), 135.9 (C), 151.4 (C), 170.4 (CO). IR: (nujol) \( \nu \) 1,750 (CO) cm⁻¹. Anal. Calcd for C₂₀H₂₃NO₂: C, 77.64; H, 7.49; N, 4.53. Found: C, 77.75; H, 7.42; N, 4.58.

**4. Conclusion**

In conclusion, we have reported a practical synthesis of the tricyclic heterocycles \( E \) incorporating the pyrazole or isoxazole framework (Figure 1). These new products share with the antipsychotic compounds \( A–C \) two substituents, namely the chlorine on the aryl ring and the 4-(1-benzyl)- or 4-(1-phenylethyl)piperidinyl group on the isoxazole and pyrazole moieties. The antipsychotic activity of these new compounds will be determined, thus indicating which further structural modifications should be pursued to advantageously modify their biological activity.

**Acknowledgements**

The authors pay their thanks to Regione Autonoma della Sardegna (RAS) for the financial support (RAS: project: CRP-26417).
Conflict of Interest

The authors declare no conflict of interest.

References and Notes

1. Ye, N.; Neumeyer, J.L.; Baldessarini, R.J.; Zhen, X.; Zhang A. Upload: Recent progress in development of dopamine receptor subtype-selective agents: Potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 2013, 113, 123–178.

2. Rowley, M.; Collins, I.; Broughton, H.B.; Davery, W.B.; Baker, R.; Emms, F.; Marwood, R.; Patel, S.; Ragan, I.C.; Freedman, S.B.; Ball, R.; Leeson, P.D. 4-Heterocyclylpiperidines as selective high-affinity ligands at the human dopamine D4 receptor. J. Med. Chem. 1997, 40, 2374–2385.

3. Pinna, G.; Pinna, G.A.; Chelucci, G.; Baldino, S. Tricyclic pyrazoles: An efficient approach to cannabinoid analogues with a tricyclic framework incorporating the pyrrole and pyrazole moieties. Synthesis 2012, 44, 2798–2804.

4. Silverman, R.R. The Organic Chemistry of Drug Design and Drug Action; Academic Press: San Diego, CA, USA, 1992.

5. Wermuth, C.G. The Practice of Medicinal Chemistry; Academic Press: San Diego, CA, USA, 1996.

6. Owton, W.M.; Brunaus, M. Synthesis of 6/7 Halotetralones. Synth. Commun. 1991, 21, 981–987.

7. Murineddu, G.; Ruiu, S.; Loriga, G.; Manca, I.; Lazzari, P.; Reali, R.; Pani, L.; Toma, L.; Pinna, G.A. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. 2005, 48, 7351–7362.

8. Cossy, J.; Belotti, D.; Bouzide, A.; Thellend, A. Short and efficient access to beta-ketoamides. Bull. Soc. Chim. Fr. 1994, 131, 723–729.

9. The structures of regioisomeric isoxazoles 7a,b,c and 8a,b,c have been confidently assigned by comparing their $^{13}$C-NMR spectra with those of the related and known open-chain isoxazoles B and C (Figure 1). Thus for instance, the $^{13}$C signals of the carbon bonded to oxygen in B and C are 166.6 ppm and 171.0 ppm, respectively, while those of 7c and 8c are 166.3 ppm and 170.7 ppm.

10. Shao, D.; Zou, C.; Cheng, L.; Tang, X.; Li, Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 2004, 14, 4639–4642.

11. Dutta, A.K.; Fei, X.S.; Beardsley, P.M.; Newman, J.L.; Reith, M.E. A. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: Evaluation of behavioral activity of O- and N-analogues and their binding to monoamine transporters. J. Med. Chem. 2001, 44, 937–948.

Sample Availability: Not available.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).